Hormonal
Combination therapy of Cagrilintide (amylin analogue) and Semaglutide (GLP-1 agonist) produces synergistic weight loss, with the 2.4 mg Cagrilintide dose achieving 17.1% weight loss over 20 weeks.
Combining Cagrilintide (an amylin analogue) with Semaglutide (a GLP-1 agonist) in a 20-week trial led to an average 17.1% weight loss, significantly better than Semaglutide alone (9.8%). This combination targets multiple hormonal pathways to suppress appetite. It is currently in Phase 1 development, and side effects were mostly mild gastrointestinal issues.
The mean percentage body weight reduction was as high as 17.1% (− 15.9 kg) for Cagrilinitide 2.4 mg and 15.7% for Cagrilinitide 1.2 mg compared to 9.8% in the pooled placebo group, all in combination with 2.4 mg Semaglutide [69].
Why this rating
Based on a single, short-term (20 weeks) Phase 1 trial with limited sample size and no lifestyle intervention.
Source
Pharmacotherapy for chronic obesity management: a look into the future
Mariana Abdel-Malek et al. · Internal and Emergency Medicine · 2023
DOI 10.1007/s11739-023-03237-4
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.Strong
- Cagrilintide, a long-acting amylin analogue, produces dose-dependent weight loss in adults with obesity, with the highest dose (4.5 mg) showing greater weight loss than Liraglutide 3.0 mg.Good
- Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss in patients with specific genetic obesity disorders (POMC, LEPR, or PCSK1 deficiency).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →